Incidence of biomarkers in high-grade gliomas and their impact on survival in a diverse SouthEast Asian cohort - a population-based study.
Activities of Daily Living
Adult
Asia, Southeastern
/ ethnology
Biomarkers, Tumor
/ genetics
Chromosomes, Human, Pair 1
/ genetics
DNA Methylation
DNA Modification Methylases
/ genetics
DNA Repair Enzymes
/ genetics
Epigenesis, Genetic
Female
Glioma
/ genetics
Humans
Incidence
Isocitrate Dehydrogenase
/ genetics
Kaplan-Meier Estimate
Male
Middle Aged
Mutation
Neoplasm Grading
Prognosis
Promoter Regions, Genetic
Retrospective Studies
Sequence Deletion
Survival Analysis
Tumor Suppressor Proteins
/ genetics
X-linked Nuclear Protein
/ genetics
1p19q
ATRX
Asian
High-grade glioma
IDH
Incidence
MGMT
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
31 Jan 2020
31 Jan 2020
Historique:
received:
11
06
2019
accepted:
13
01
2020
entrez:
2
2
2020
pubmed:
2
2
2020
medline:
2
10
2020
Statut:
epublish
Résumé
Gliomas consist of a heterogeneous group of tumors. This study aimed to report the incidences of O Records of patients who underwent surgery for high-grade gliomas from January 2013 to March 2017 at our institution were obtained. The patients' age, gender, ethnicity, Karnofsky Performance Scale (KPS) score, ability to perform activities of daily living (ADLs), tumor location and biomarkers status were recorded. Data were analyzed using chi-square and Mann-Whitney U tests, Kaplan-Meier estimates and log-rank test. 181 patients were selected (56 with grade III gliomas, 125 with grade IV gliomas). In the grade III group, 55% had MGMT promoter methylation, 41% had 1p19q co-deletion, 35% had IDH1 mutation and none had ATRX loss. In the grade IV group, 30% had MGMT promoter methylation, 2% had 1p19q co-deletion, 15% had IDH1 mutation and 8% had ATRX loss. After adjusting for effects of age, surgery and pre-operative ADL statuses, only MGMT promoter methylation was found to be significantly associated with longer overall survival time in grade III (p = 0.024) and IV patients (p = 0.006). The incidences of MGMT promoter methylation and IDH1 mutation were found to be comparable to globally reported rates, but those of 1p19q co-deletion and ATRX loss seemed to be lower in our cohort. MGMT promoter methylation was associated with increased overall survival in our cohort and might serve as favorable prognostic factor.
Sections du résumé
BACKGROUND
BACKGROUND
Gliomas consist of a heterogeneous group of tumors. This study aimed to report the incidences of O
METHODS
METHODS
Records of patients who underwent surgery for high-grade gliomas from January 2013 to March 2017 at our institution were obtained. The patients' age, gender, ethnicity, Karnofsky Performance Scale (KPS) score, ability to perform activities of daily living (ADLs), tumor location and biomarkers status were recorded. Data were analyzed using chi-square and Mann-Whitney U tests, Kaplan-Meier estimates and log-rank test.
RESULTS
RESULTS
181 patients were selected (56 with grade III gliomas, 125 with grade IV gliomas). In the grade III group, 55% had MGMT promoter methylation, 41% had 1p19q co-deletion, 35% had IDH1 mutation and none had ATRX loss. In the grade IV group, 30% had MGMT promoter methylation, 2% had 1p19q co-deletion, 15% had IDH1 mutation and 8% had ATRX loss. After adjusting for effects of age, surgery and pre-operative ADL statuses, only MGMT promoter methylation was found to be significantly associated with longer overall survival time in grade III (p = 0.024) and IV patients (p = 0.006).
CONCLUSIONS
CONCLUSIONS
The incidences of MGMT promoter methylation and IDH1 mutation were found to be comparable to globally reported rates, but those of 1p19q co-deletion and ATRX loss seemed to be lower in our cohort. MGMT promoter methylation was associated with increased overall survival in our cohort and might serve as favorable prognostic factor.
Identifiants
pubmed: 32005184
doi: 10.1186/s12885-020-6536-x
pii: 10.1186/s12885-020-6536-x
pmc: PMC6993394
doi:
Substances chimiques
Biomarkers, Tumor
0
Tumor Suppressor Proteins
0
Isocitrate Dehydrogenase
EC 1.1.1.41
IDH1 protein, human
EC 1.1.1.42.
DNA Modification Methylases
EC 2.1.1.-
MGMT protein, human
EC 2.1.1.63
ATRX protein, human
EC 3.6.4.12
X-linked Nuclear Protein
EC 3.6.4.12
DNA Repair Enzymes
EC 6.5.1.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
79Subventions
Organisme : National Medical Research Council
ID : NMRC/TCR/016-NNI/2016
Références
Clin Neurol Neurosurg. 2016 Dec;151:31-36
pubmed: 27764705
Cell. 1995 Mar 24;80(6):837-45
pubmed: 7697714
Acta Neuropathol. 2013 Sep;126(3):443-51
pubmed: 23904111
J Clin Oncol. 2009 Dec 10;27(35):5881-6
pubmed: 19901104
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
Neurol India. 2012 Sep-Oct;60(5):481-6
pubmed: 23135024
Am J Pathol. 1994 Nov;145(5):1175-90
pubmed: 7977648
Acta Neuropathol. 2017 Jun;133(6):1001-1016
pubmed: 28255664
Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86
pubmed: 30445539
Neurosurg Focus. 2015 Mar;38(3):E4
pubmed: 25727226
Neuropathology. 2015 Aug;35(4):324-35
pubmed: 25950388
Neuro Oncol. 2011 Jun;13(6):649-59
pubmed: 21636710
Expert Opin Ther Targets. 2018 Jul;22(7):599-613
pubmed: 29889582
Onco Targets Ther. 2013 Sep 27;6:1363-72
pubmed: 24109190
Clin Neurol Neurosurg. 2016 Oct;149:15-21
pubmed: 27450763
Pharmacol Rev. 2018 Jul;70(3):412-445
pubmed: 29669750
Curr Oncol Rep. 2017 Apr;19(4):26
pubmed: 28303493
Acta Neuropathol Commun. 2016 Jun 16;4(1):60
pubmed: 27311324
Brain Pathol. 2003 Apr;13(2):176-84
pubmed: 12744471
Cancer Res. 2018 Jun 1;78(11):2966-2977
pubmed: 29545335
J Clin Oncol. 2013 Jan 20;31(3):337-43
pubmed: 23071247
J Neurooncol. 2002 Nov;60(2):117-25
pubmed: 12635658
Control Clin Trials. 1996 Aug;17(4):343-6
pubmed: 8889347
Cancer Manag Res. 2017 Sep 20;9:411-425
pubmed: 29033608
Int J Mol Sci. 2018 Jun 14;19(6):null
pubmed: 29899215
Cancer Res. 2001 May 15;61(10):3949-54
pubmed: 11358811
Clin Cancer Res. 2013 Feb 15;19(4):764-72
pubmed: 23209033
Science. 2008 Sep 26;321(5897):1807-12
pubmed: 18772396
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Cancer. 2012 Sep 15;118(18):4545-54
pubmed: 22359215
Front Oncol. 2017 Sep 29;7:236
pubmed: 29034211
J Clin Oncol. 2009 Dec 10;27(35):5874-80
pubmed: 19901110
Anticancer Res. 2016 Jan;36(1):471-6
pubmed: 26722084
Am J Pathol. 2009 Apr;174(4):1149-53
pubmed: 19246647
J Neurooncol. 1993 Jul;17(1):47-64
pubmed: 8120572
Folia Biol (Praha). 2016;62(5):194-202
pubmed: 27978414
Southeast Asian J Trop Med Public Health. 2005 May;36(3):748-56
pubmed: 16124450
Oncotarget. 2016 Mar 29;7(13):16384-95
pubmed: 26918938
J Korean Med Sci. 2016 Aug;31(8):1208-14
pubmed: 27478330
Med Oncol. 2012 Jun;29(2):1292-6
pubmed: 21394635
Mod Pathol. 2013 Jul;26(7):922-9
pubmed: 23429602
PLoS One. 2013 Jul 22;8(7):e68782
pubmed: 23894344
Oncol Lett. 2015 May;9(5):2063-2067
pubmed: 26137013
J Neurooncol. 2012 May;107(3):617-31
pubmed: 22287028
J Clin Pathol. 2016 Aug;69(8):686-94
pubmed: 26743027
Cancer. 2013 Oct 1;119(19):3489-95
pubmed: 23868553
Oncotarget. 2015 Dec 1;6(38):40896-906
pubmed: 26503470
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
J Clin Oncol. 2013 Jan 20;31(3):344-50
pubmed: 23071237
N Engl J Med. 2014 Feb 20;370(8):709-22
pubmed: 24552318